Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer
P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler
The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.
bioRxiv · Oct 23, 2017Cancer Biology